leisure time -WSS

leisure time

author：explore 2025-08-12 09:09:08 - browse：6

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： What is artificial intelligence? Experts weigh in

WSS

Analysis of telehealth claims data suggest service duplication

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

Chemotherapy drug shortage eases slightly but still widespread

FDA panel signals lack of confidence in Amgen cancer drug data

Stroke deaths set to near 10 million globally by 2050

What is artificial intelligence? Experts weigh in

hotspot

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Medical records are filled with copy

Was Amgen transparent enough on FDA's concern on cancer drug?

Hollywood unions extend contract negotiations for actors

Bill would stop addiction treatment from triggering child abuse inquiry

Psychedelics group wrestles with new pharma identity

Why age limits for politicians are a terrible idea

State Dept. review finds Biden bears some blame for Afghanistan failures

Pfizer's RSV vaccine recommended for approval in Europe

23andMe had bad news about my health. I wish a person had delivered it

Senate panel eyes new effort on drug shortages

focus

Family of Gilgo Beach murder suspect releases statement: 'Devastating time'

Analysis of telehealth claims data suggest service duplication

Chemotherapy drug shortage eases slightly but still widespread

Why Marc Tessier

Colorectal cancer study finds potential in overlooked immune cell

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

focus

knowledge

entertainment

entertainment